Pasithea Therapeutics Corp. SEC filings KTTA
Pasithea Therapeutics Corp. has 344 filings in SEC EDGAR's recent list, going back to Jan 29, 2021. Its latest annual report, Form ARS, was filed on Aug 7, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 16, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 25-NSE | Delisting notice | Sep 16, 2026 | — |
| EFFECT | Filing | Jan 27, 2026 | — |
| EFFECT | Filing | Nov 28, 2025 | — |
| CORRESP | Letter to the SEC | Nov 26, 2025 | — |
| CORRESP | Letter to the SEC | Nov 26, 2025 | — |
| CORRESP | Letter to the SEC | Nov 24, 2025 | — |
| CORRESP | Letter to the SEC | Nov 24, 2025 | — |
| CORRESP | Letter to the SEC | Nov 21, 2025 | — |
| CORRESP | Letter to the SEC | Nov 21, 2025 | — |
| CORRESP | Letter to the SEC | Nov 21, 2025 | — |
| CORRESP | Letter to the SEC | Nov 21, 2025 | — |
| CORRESP | Letter to the SEC | Nov 19, 2025 | — |
| CORRESP | Letter to the SEC | Nov 19, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 2, 2025 | — |
| DRS | Filing | Aug 28, 2025 | — |
| DRSLTR | Filing | Aug 27, 2025 | — |
| EFFECT | Filing | May 6, 2025 | — |
| CORRESP | Letter to the SEC | May 1, 2025 | — |
| CORRESP | Letter to the SEC | May 1, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 14, 2025 | — |
| DRS | Filing | Apr 7, 2025 | — |
| EFFECT | Filing | Oct 11, 2024 | — |
| CORRESP | Letter to the SEC | Oct 10, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 10, 2024 | — |
| EFFECT | Filing | Apr 2, 2024 | — |
| SC TO-I/A | Amendment no. 4 to form sc to-i | Sep 14, 2023 | — |
| SC TO-I/A | Filing | Aug 24, 2023 | — |
| SC TO-I/A | Filing | Aug 21, 2023 | — |
| CORRESP | Letter to the SEC | Aug 21, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 15, 2023 | — |
| SC TO-I/A | Filing | Aug 14, 2023 | — |
| SC TO-I | Filing | Aug 9, 2023 | — |
| SC TO-C | Current report | Jul 20, 2023 | — |
| EFFECT | Filing | Jun 5, 2023 | — |
| CORRESP | Letter to the SEC | Jun 1, 2023 | — |
| UPLOAD | Letter from the SEC | May 19, 2023 | — |
| DEL AM | Delaying amendment | May 17, 2023 | — |
| EFFECT | Filing | Apr 19, 2023 | — |
| CORRESP | Letter to the SEC | Apr 17, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 4, 2023 | — |
| DFAN14A | Filing | Dec 7, 2022 | — |
| DFAN14A | Filing | Nov 22, 2022 | — |
| DEFC14A | Filing | Nov 17, 2022 | — |
| DEFC14A | Proxy statement | Nov 15, 2022 | — |
| CORRESP | Letter to the SEC | Nov 14, 2022 | — |
| PRER14A | Revised preliminary statement | Nov 14, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 7, 2022 | — |
| PREC14A | Filing | Nov 1, 2022 | — |
| DFAN14A | Filing | Oct 13, 2022 | — |
| PRRN14A | Filing | Oct 12, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 30, 2022 | — |
| DFAN14A | Filing | Sep 29, 2022 | — |
| PREC14A | Filing | Sep 23, 2022 | — |
| DFAN14A | Filing | Sep 6, 2022 | — |
| DFAN14A | Filing | Aug 24, 2022 | — |
| DFAN14A | Filing | Aug 5, 2022 | — |
| DEFC14A | Definitive proxy statement | Jul 28, 2022 | — |
| DFAN14A | Filing | Jul 26, 2022 | — |
| PREC14A | Preliminary proxy statement | Jul 26, 2022 | — |
| DEFC14A | Filing | Jul 14, 2022 | — |
| PRRN14A | Filing | Jul 13, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 8, 2022 | — |
| PREC14A | Filing | Jul 1, 2022 | — |
| DFAN14A | Filing | Jun 23, 2022 | — |
| EFFECT | Filing | Dec 16, 2021 | — |
| CORRESP | Letter to the SEC | Dec 14, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 14, 2021 | — |
| D | Filing | Dec 7, 2021 | — |
| NT 10-Q | Notification of late filing | Nov 16, 2021 | Sep 30, 2021 |
| EFFECT | Filing | Sep 14, 2021 | — |
| CERT | Filing | Sep 14, 2021 | — |
| 8-A12B | Form 8-a12b | Sep 13, 2021 | — |
| CORRESP | Letter to the SEC | Sep 10, 2021 | — |
| CORRESP | Letter to the SEC | Sep 10, 2021 | — |
| CORRESP | Letter to the SEC | Aug 26, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 11, 2021 | — |
| CORRESP | Letter to the SEC | Aug 5, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 1, 2021 | — |
| CORRESP | Letter to the SEC | Jun 21, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 16, 2021 | — |
| CORRESP | Letter to the SEC | Jun 4, 2021 | — |
| UPLOAD | Letter from the SEC | May 10, 2021 | — |
| D | Filing | Mar 19, 2021 | — |
| D | Filing | Jan 29, 2021 | — |
Showing 84 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KTTA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Miami Beach, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1841330
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.